February 26, 2018 / 9:24 PM / in 8 months

BRIEF-Valneva And Emergent Biosolutions Start Phase 1 Clinical Study To Evaluate Vaccine Candidate Against Zika Virus

Feb 26 (Reuters) - VALNEVA SE:

* EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUS

* ‍INITIAL DATA FROM TRIAL ARE EXPECTED TO BE AVAILABLE IN LATE 2018 OR EARLY 2019​

* AFTER PHASE 1 DATA, EMERGENT HAS OPTION TO DEVELOP VACCINE UNDER LICENSE AGREEMENT WITH VALNEVA AT EUR 5 MILLION​

* LICENSE ‍AGREEMENT PROVIDES VALNEVA POTENTIAL ADDITIONAL MILESTONE PAYMENTS OF UP TO EUR 44 MILLION​

* LICENSE ‍AGREEMENT TO GIVE CO RIGHT TO NEGOTIATE WITH EMERGENT EXCLUSIVE COMMERCIALIZATION RIGHTS IN EUROPE​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below